Literature DB >> 9808098

Dialysis unit and patient characteristics associated with reuse practices and mortality: 1989-1993.

A J Collins1, J Z Ma, E G Constantini, S E Everson.   

Abstract

The diverse patient and dialysis unit characteristics in the United States pose challenges for assessing the safety and efficacy of reuse practices. A 10% random sample of period-prevalent hemodialysis patients from units practicing conventional dialysis (<25% of patients with high-efficiency/high-flux dialysis) were analyzed. The data included 13,926 patient observations in 1989-1990 and 20,422 in 1991-1993. Centers for Disease Control and Prevention and Health Care Financing Administration facility survey Medicare data were analyzed with a Cox regression model, evaluating the risk of reuse compared with no reuse and adjusting for comorbidity, unit characteristics, and profit status. In 1989-1990, freestanding and hospital-based units that did not reuse dialyzers were not significantly different from each other in mortality rates. In 1991-1993, however, no-reuse, freestanding, for-profit units had higher risks (relative risk [RR] = 1.23, P = 0.003) compared with no-reuse, hospital-based, nonprofit units. No-reuse, hospital-based, for-profit units, in contrast, were associated with a lower mortality risk (RR = 0.70, P = 0.0001). An isolated higher risk associated with peracetic acid manual reuse in freestanding units (1989-1990) was identified in for-profit units only. In the 1991-1993 period, an increased mortality risk was noted in hospital-based, nonprofit units practicing formaldehyde automatic reuse, and in freestanding, for-profit units using glutaraldehyde, which accounted for <5% of all units. All other interactions of reuse germicide and technique were not different from no-reuse. The varying mortality rates identified in both no-reuse and reuse units using conventional dialysis suggest that other factors, such as dialysis therapy and anemia correction (both known predictors of patient survival), have a greater influence on U.S. mortality than reuse germicides and techniques.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9808098     DOI: 10.1681/ASN.V9112108

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  6 in total

1.  Dialyzer reuse with peracetic acid does not impact patient mortality.

Authors:  T Christopher Bond; Allen R Nissenson; Mahesh Krishnan; Steven M Wilson; Tracy Mayne
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-12       Impact factor: 8.237

2.  Survival of kidney transplantation patients in the United States after cardiac valve replacement.

Authors:  Alok Sharma; David T Gilbertson; Charles A Herzog
Journal:  Circulation       Date:  2010-06-14       Impact factor: 29.690

3.  Outcomes of Surgical Mitral and Aortic Valve Replacements Among Kidney Transplant Candidates: Implications for Valve Selection.

Authors:  David K Ngendahimana; Salil V Deo; Varun Sundaram; Krista L Lentine; Charles A Herzog; Laith Al Dahabreh; Titte R Srinivas; Kenneth D Chavin; Nagaraju Sarabu
Journal:  J Am Heart Assoc       Date:  2021-02-18       Impact factor: 5.501

4.  Dialyzer Reuse and Outcomes of High Flux Dialysis.

Authors:  Christos Argyropoulos; Maria-Eleni Roumelioti; Abdus Sattar; John A Kellum; Lisa Weissfeld; Mark L Unruh
Journal:  PLoS One       Date:  2015-06-09       Impact factor: 3.240

5.  Clinical and microbiological effects of dialyzers reuse in hemodialysis patients.

Authors:  Isabella Carvalho Ribeiro; Noemí Angelica Vieira Roza; Diego Andreazzi Duarte; Dioze Guadagnini; Rosilene Motta Elias; Rodrigo Bueno de Oliveira
Journal:  J Bras Nefrol       Date:  2019-01-24

6.  Comparative mortality of hemodialysis patients at for-profit and not-for-profit dialysis facilities in the United States, 1998 to 2003: a retrospective analysis.

Authors:  Robert N Foley; Qiao Fan; Jiannong Liu; David T Gilbertson; Eric D Weinhandl; Shu-Cheng Chen; Allan J Collins
Journal:  BMC Nephrol       Date:  2008-06-26       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.